Form 4: Chaitan Khosla, Entero Therapeutics Director, Acquires Shares Through Restricted Stock Units

Director Chaitan Khosla receives 24,889 restricted stock units in Entero Therapeutics, vesting in three equal installments.

Summary

• Chaitan Khosla, a director of Entero Therapeutics, Inc., received 24,889 restricted stock units (RSUs) on June 11, 2024.
• These RSUs will be settled in shares of common stock with a par value of $0.0001.
• The RSUs vest in three equal increments on July 1, 2024, September 30, 2024, and December 31, 2024.
• Following the transaction, Khosla directly owns 24,889 shares, including unvested RSUs, and indirectly owns 440 shares through the Chaitan Khosla Living Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a standard transaction of a director receiving restricted stock units, which is generally viewed as a positive sign of alignment with shareholder interests, but not significantly impactful on its own.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's increased stake in the company.

Key Dates

Keywords

Entero Therapeutics, Chaitan Khosla, restricted stock units, RSUs, Form 4, beneficial ownership, director, ENTRO